297 related articles for article (PubMed ID: 21514287)
21. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
[TBL] [Abstract][Full Text] [Related]
22. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
23. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease.
Piemonte F; Petrini S; Gaeta LM; Tozzi G; Bertini E; Devito R; Boldrini R; Marcellini M; Ciacco E; Nobili V
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e457-64. PubMed ID: 17683488
[TBL] [Abstract][Full Text] [Related]
24. Oxidative mechanisms in the pathogenesis of alcoholic liver disease.
Albano E
Mol Aspects Med; 2008; 29(1-2):9-16. PubMed ID: 18045675
[TBL] [Abstract][Full Text] [Related]
25. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
[TBL] [Abstract][Full Text] [Related]
26. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
27. Role of mitochondria in non-alcoholic fatty liver disease.
Pessayre D
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S20-7. PubMed ID: 17567459
[TBL] [Abstract][Full Text] [Related]
28. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity.
Valenzuela R; Videla LA
Food Funct; 2011 Nov; 2(11):644-8. PubMed ID: 22008843
[TBL] [Abstract][Full Text] [Related]
29. Role of adipocytokines in hepatic fibrogenesis.
Ikejima K; Okumura K; Kon K; Takei Y; Sato N
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
[TBL] [Abstract][Full Text] [Related]
30. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.
Marra F; Gastaldelli A; Svegliati Baroni G; Tell G; Tiribelli C
Trends Mol Med; 2008 Feb; 14(2):72-81. PubMed ID: 18218340
[TBL] [Abstract][Full Text] [Related]
32. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis.
Sozio MS; Liangpunsakul S; Crabb D
Semin Liver Dis; 2010 Nov; 30(4):378-90. PubMed ID: 20960377
[TBL] [Abstract][Full Text] [Related]
33. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease.
McCarty MF
Med Hypotheses; 2011 Oct; 77(4):550-6. PubMed ID: 21764223
[TBL] [Abstract][Full Text] [Related]
34. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
Reddy JK; Rao MS
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G852-8. PubMed ID: 16603729
[TBL] [Abstract][Full Text] [Related]
35. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
Carter-Kent C; Zein NN; Feldstein AE
Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
[TBL] [Abstract][Full Text] [Related]
36. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
37. Role of oxidative stress and Kupffer cells in hepatic fibrosis.
Kawada N; Otogawa K
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S85-6. PubMed ID: 17567475
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial dysfunction in nonalcoholic steatohepatitis.
Serviddio G; Bellanti F; Vendemiale G; Altomare E
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):233-44. PubMed ID: 21476918
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of disease progression in nonalcoholic fatty liver disease.
Jou J; Choi SS; Diehl AM
Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
